BioVie Inc. (Class A) (BIVI) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, BIVI carries a score of 32 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 4 out of 20, reflecting ROIC of -35% and FCF yield of 0%. The whale 13F flow pillar scores 5 out of 20, covering institutional accumulation and options positioning. The insider conviction pillar scores 5 out of 20, covering SEC Form 4 and Congressional PTR cluster flow. The macro regime fit pillar scores 8 out of 20, reflecting a beta of 1.0 and sector sensitivity. The forensic balance sheet pillar scores 10 out of 20, reflecting an Altman Z of 2.5, a Piotroski F of 2/9, and a Debt/Equity of 0.5.

For a prospective investor, the pillar profile indicates that the weakest areas are cash generation and insider or institutional conviction, both of which score in the lower range. The upside case in this framework depends on a reversal in cash generation, which the source data does not show occurring. The forensic balance sheet pillar is the strongest of the five, though it still scores below half its maximum. Valuation tradeoffs cannot be assessed directly because P/E, forward P/E, and EV/EBITDA are not available in source data. The most visible ripple is the gap between the stock's reported cash balance and its recent cash burn, which the financial trend section below quantifies.

BioVie Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the profile section. The source data does not identify its specific products, customers, or revenue model. Reported revenue is $0.0M across all listed periods per the SEC financials. Market capitalization is $12.0M per the market data section.

Per the SEC financials, the company reported zero revenue and net losses in each listed period, with operating losses narrowing from $-45.1M in FY 2023 to $-18.1M in FY 2025. Gross, operating, and net margins are each recorded as 0% in the market data section, and ROIC is -35%. The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 are reported in the Roarable RQD rating. Debt/Equity is 0.5 per the same source, while the financials list debt as N/A for every period.

Per the recent news and catalysts section, the feed contains six headlines, each tagged with a YELLOW signal and labeled MARKET WIRE. Catalyst themes include a Long COVID fatigue trial result, a Parkinson's and Long COVID study with results to be presented in San Diego, and a trial symptom analysis noting that about 78% of patients had at least one of three symptoms. One headline reports a price of $1.48 in a symmetrical triangle pattern. Several items come from aggregator sources, and one summary field is an unrelated website URL, so the reliability of the summaries is limited. The butterfly supply-chain graph lists no supply chain and no butterfly links or proprietary signals.

• What specific products or clinical programs generate the catalysts described in the news feed, and what is their regulatory stage?
• What is the company's cash runway given FY 2025 FCF of $-19.0M against a reported cash balance of $20.5M?
• Why are debt figures listed as N/A in every financial period while the RQD rating reports Debt/Equity of 0.5?
• What is the source of the Altman Z, Piotroski F, and insider or 13F scores, and what underlying filings were used?
• What are the EPS, P/E, and EV/EBITDA values, which are absent from the source data?